Capricor Therapeutics Files 8-K on Financials
Ticker: CAPR · Form: 8-K · Filed: May 13, 2024 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, pharmaceuticals
Related Tickers: CAPR
TL;DR
CAPR filed an 8-K on 5/13/24 covering financial results.
AI Summary
On May 13, 2024, Capricor Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry. This filing serves as a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing provides investors with an update on Capricor Therapeutics' financial condition and operational status, which is crucial for evaluating the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Numbers
- 20240513 — Filing Date (Indicates the date the 8-K was submitted to the SEC.)
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Registrant
- May 13, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-34058 (company_id) — SEC File Number
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 8-K filing by Capricor Therapeutics, Inc.?
The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, detailing the company's results of operations and financial condition, as well as financial statements and exhibits.
When was this 8-K report filed?
The report was filed on May 13, 2024.
What is Capricor Therapeutics, Inc.'s state of incorporation?
Capricor Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Capricor Therapeutics, Inc.?
The SEC file number for Capricor Therapeutics, Inc. is 001-34058.
What industry does Capricor Therapeutics, Inc. operate in, according to its SIC code?
Capricor Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, indicated by the Standard Industrial Classification code 2834.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-13 16:05:49
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M
Filing Documents
- capr-20240513x8k.htm (8-K) — 37KB
- capr-20240513xex99d1.htm (EX-99.1) — 128KB
- capr-20240513xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-007958.txt ( ) — 301KB
- capr-20240513.xsd (EX-101.SCH) — 3KB
- capr-20240513_lab.xml (EX-101.LAB) — 15KB
- capr-20240513_pre.xml (EX-101.PRE) — 9KB
- capr-20240513x8k_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. On May 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company's filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, titled "Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update" dated May 13, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: May 13, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3